Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
19.42B
Market cap19.42B
Price-Earnings ratio
-7.28
Price-Earnings ratio-7.28
Dividend yield
Dividend yield
Average volume
9.54M
Average volume9.54M
High today
$52.04
High today$52.04
Low today
$48.09
Low today$48.09
Open price
$50.16
Open price$50.16
Volume
3.49M
Volume3.49M
52 Week high
$55.20
52 Week high$55.20
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

The current Moderna(MRNA) stock price is $49.17, with a market capitalization of 19.42B. The stock trades at a price-to-earnings (P/E) ratio of -7.28.

On 2026-03-03, Moderna(MRNA) stock moved within a range of $48.09 to $52.04. With shares now at $49.17, the stock is trading +2.2% above its intraday low and -5.5% below the session's peak.

Trading volume for Moderna(MRNA) stock has reached 3.49M, versus its average volume of 9.54M.

The stock's 52-week range extends from a low of $22.28 to a high of $55.20.

The stock's 52-week range extends from a low of $22.28 to a high of $55.20.

MRNA News

TipRanks 4d
Moderna receives positive CHMP opinion for mCOMBRIAX

Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketi...

Simply Wall St 5d
Moderna Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine

In February 2026, Moderna’s mRNA-based seasonal flu vaccine application, initially rejected by the U.S. Food and Drug Administration over trial design concerns,...

Moderna Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine
The Motley Fool 6d
Moderna's Ups and Downs: Here's What You Need to Know Before Investing.

The stock, after a few tough years, soared in the double-digits in January. Moderna (MRNA +0.46%) soared into the spotlight during the pandemic thanks to its m...

Moderna's Ups and Downs: Here's What You Need to Know Before Investing.

Analyst ratings

73%

of 26 ratings
Buy
11.5%
Hold
73.1%
Sell
15.4%

More MRNA News

Simply Wall St 7d
FDA Reopens Review Of Moderna Flu Shot And Shifts Investor Focus

The U.S. FDA is now reviewing Moderna’s mRNA flu vaccine application after previously issuing a Refusal to File tied to the study’s choice of comparator. This...

FDA Reopens Review Of Moderna Flu Shot And Shifts Investor Focus

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.